The incidence of CIED infection in the U.S. has been increasing for the past two decades, according to work published in JACC: Clinical Electrophysiology this month.

Just weeks after it fast-tracked dapagliflozin for the treatment of chronic kidney disease, the FDA announced it was granting Fast Track status to the drug for another indication: heart failure.

Research out of the Cummings School of Veterinary Medicine at Tufts University suggests focused cardiac ultrasound, rather than a full echo workup, might be an effective way of screening for CVD in cats.

The American Society of Nuclear Cardiology, together with eight other nuclear medicine and cardiology societies, have published a consensus document outlining the best practices for imaging and diagnosing cardiac amyloidosis.

The FDA announced Sept. 13 it identified low levels of N-nitrosodimethylamine, or NDMA, in popular heartburn drugs including Zantac.

Apple announced the initiation of three new large-scale medical studies, including one focused on women’s health, one focused on hearing and one focused on cardiovascular health and movement.

Contrary to a recent FDA advisory that acknowledged a late mortality signal with paclitaxel-coated and -eluting devices, a study published in the Journal of Endovascular Therapy found such stents safe in the long-term for treating femoropopliteal lesions in people with peripheral artery disease.

Men who struggle with erectile dysfunction—especially more severe cases—are at an increased risk of CHD, total heart disease, stroke and all-cause mortality, according to research published in the Journal of Sexual Medicine.

Discharging patients with suspected acute coronary syndrome (ACS) under a 0- and 1-hour high-sensitivity cardiac troponin T protocol is helpful for clearing waiting rooms, according to work presented at the ESC Congress Sept. 3.